The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Key challenges in overcoming resistance to FLT3 inhibitors in AML
In this video, Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, comments on the challenges of overcoming resistance to FLT3 inhibitors in acute myeloid leukemia (AML), noting that the mechanisms of resistance in frontline therapy may differ from those in relapsed/refractory settings. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
